Lantheus Holdings, Inc.
LNTH scores 49.6 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (0.0 points) applied. LNTH's rank of #570 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| LNTH | 49.6 | 29.6 | 18.3% | 11.0% | $5.2B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 85.6 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 82.1 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $121.8B |
| ASND | 75.8 | 16.6 | 98.0% | -31.7% | $13.8B |
| NBIX | 74.8 | 26.5 | 21.4% | 16.7% | $13.1B |
| AMGN | 73.9 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.5 | 35.1 | 78.6% | 38.0% | $47.4B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.4 | 19.4 | 1.0% | 31.4% | $80.2B |
| ISRG | 72.2 | 61.7 | 20.5% | 28.4% | $180.9B |
| EXEL | 71.6 | 15.1 | 7.0% | 33.7% | $11.9B |
| ALKS | 71.5 | 16.5 | -6.4% | 23.9% | $5.0B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $7.9B |
| HALO | 70.3 | 16.8 | 22.4% | 43.7% | $8.2B |
| Sector Average | 37.0 | 41.9 | 161.5% | -3292.7% | — |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $407M | $384M | $378M | $373M |
| Gross Profit | $241M | $222M | $241M | $238M |
| Operating Income | $77M | $44M | $88M | $102M |
| Net Income | $54M | $28M | $79M | $73M |
| EPS (Diluted) | $0.82 | $0.41 | $1.12 | $1.02 |
| Gross Margin | 59.2% | 57.9% | 63.8% | 63.8% |
| Operating Margin | 19.0% | 11.4% | 23.3% | 27.4% |
| Net Margin | 13.3% | 7.2% | 20.8% | 19.6% |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.